Three new Cochrane reviews find evidence that GLP-1 drugs lead to clinically meaningful weight loss, though industry-funded studies raise concerns.
Three new reviews from Cochrane have found that GLP-1 medications can lead to significant weight loss, though questions remain about the influence of industry-funded research. Commissioned by the World Health Organization (WHO), these reviews will help shape forthcoming global guidelines on using these drugs to treat obesity.
The analyses focused on three medications known as GLP-1 receptor agonists and concluded that each produced clinically meaningful weight loss when compared with a placebo. However, researchers noted that data on long-term effects, side effects, and possible conflicts of interest are still uncertain or incomplete.
Glucagon-like peptide-1 (GLP-1) receptor agonists were first developed in the mid-2000s to help manage type 2 diabetes. In patients with this condition, particularly those with heart or kidney disease, the drugs improved blood sugar control, lowered the risk of related complications, aided in weight reduction, and decreased the likelihood of premature death.
In recent years, these drugs have also been tested in people with obesity. By mimicking a natural hormone that slows digestion and promotes a sense of fullness, they can help reduce food intake. In the United Kingdom, GLP-1 receptor agonists are now approved for weight management in individuals with obesity, or in those who are overweight with health conditions linked to excess weight, when combined with a calorie-controlled diet and physical activity.
GLP-1 Drugs: Generic [and Brand Names]:
- Semaglutide [Ozempic, Wegovy, Rybelsus]
- Liraglutide [Victoza, Saxenda]
- Dulaglutide [Trulicity]
- Exenatide [Byetta, Bydureon]
- Tirzepatide (GLP-1/GIP dual agonist) [Mounjaro, Zepbound]
GLP-1 drugs show promise for weight management
Across the reviews, tirzepatide, semaglutide, and liraglutide each led to significant weight loss compared to placebo after one to two years, with these effects likely to be sustained while treatment continues.
- Tirzepatide (administered once weekly) resulted in approximately a 16% weight reduction after 12 to 18 months. Evidence from 8 randomized controlled trials (6,361 participants) also suggested these effects could be maintained for up to 3.5 years, although long-term safety data were limited.
- Semaglutide (also injected weekly) reduced body weight by around 11% after 24 to 68 weeks, with effects likely sustained up to two years, drawing on 18 randomized controlled trials (27,949 participants). The drug increased the likelihood of achieving at least 5% body weight loss but was associated with higher rates of mild-to-moderate gastrointestinal side effects.
- Liraglutide (a daily injection) resulted in a more modest average weight reduction of around 4–5%, based on 24 trials (9,937 participants), but still increased the proportion of people achieving meaningful weight loss compared with placebo. Evidence for longer-term effects beyond two years was more limited.
Across the reviews, there was little to no difference between these drugs and placebo for major cardiovascular events, quality of life, or mortality. However, adverse events, particularly nausea and digestive symptoms, were more common among participants taking GLP-1 drugs, and some stopped treatment due to side effects.
“These drugs have the potential to bring about substantial weight loss, particularly in the first year,” says Juan Franco, co-lead researcher from Heinrich Heine University Düsseldorf, Germany. “It’s an exciting moment after decades of unsuccessful attempts to find effective treatments for people living with obesity.”
Independent research and equitable access are key
Most included studies were funded by the drug manufacturers, who were substantially involved in the planning, conduct, analysis, and reporting of the results. This raises concerns about potential conflicts of interest and the need for independent research.
The authors also emphasized that the wider use of these drugs should consider social and commercial determinants of health, including access, affordability, and insurance coverage, to avoid deepening existing health inequities among people living with obesity. The high prices of semaglutide and tirzepatide currently limit access, while liraglutide’s expired patent has allowed for more affordable generic versions to become available. Semaglutide’s patent will also expire in 2026.
Studies included in all three reviews were conducted mainly in middle- and high-income countries, with limited or no representation from regions such as Africa, Central America, and Southeast Asia. Considering the diversity in body composition, diet, and health behaviors across populations, the authors note the importance of assessing how these drugs perform in different global contexts.
“We need more data on the long-term effects and other outcomes related to cardiovascular health, particularly in lower-risk individuals,” says Eva Madrid, co-lead researcher from the Universidad de Valparaíso, Chile. “Weight regain after stopping treatment may affect the long-term sustainability of the observed benefits. More independent studies from a public health perspective are needed.”
The reviews stress that independent, long-term investigations are essential to inform clinical and public policy decisions and to better establish the role of GLP-1 receptor agonists in long-term weight management.
Commissioned by the World Health Organization, these reviews will inform forthcoming WHO guidelines on the use of GLP-1 receptor agonists for treating obesity. The guidelines are expected to launch soon, following a public consultation held in September.
References:
“Liraglutide for adults living with obesity” by Nicolás Meza, Javier Bracchiglione, Camila Micaela Escobar Liquitay, Eva Madrid, Lucia B Varela, Yang Guo, Gerard Urrútia, Selcuk Er, Sandra Tiller, Kamyar Shokraee, Felipe Alvarez Busco, Ivan Solà, Miranda Ocara Vargas, Victoria Novik A, Daniel Poloni and Juan VA Franco, 30 October 2025, Cochrane Database of Systematic Reviews.
DOI: 10.1002/14651858.CD016017
“Semaglutide for adults living with obesity” by Javier Bracchiglione, Nicolás Meza, Juan VA Franco, Camila Micaela Escobar Liquitay, Victoria Novik A, Miranda Ocara Vargas, Gabriel Lazcano, Daniel Poloni, Francisca Rinaldi Langlotz, Marta Roqué-Figuls, Sergio R Munoz and Eva Madrid, 30 October 2025, Cochrane Database of Systematic Reviews.
DOI: 10.1002/14651858.CD015092.pub2
“Tirzepatide for adults living with obesity” by Juan VA Franco, Yang Guo, Lucia B Varela, Zakariya Aqra, Murad Alhalahla, Mauricio Medina Rodriguez, Edison Leonardo Salvador Oscco, Bernarda Patiño Araujo, Susan Banda, Camila Micaela Escobar Liquitay, Javier Bracchiglione, Nicolás Meza and Eva Madrid, 30 October 2025, Cochrane Database of Systematic Reviews.
DOI: 10.1002/14651858.CD016018
News
Scientists Discover Why Some COVID Survivors Still Can’t Taste Food Years Later
A new study provides the first direct biological evidence explaining why some people continue to experience taste loss long after recovering from COVID-19. Researchers have uncovered specific biological changes in taste buds that could help [...]
Catching COVID significantly raises the risk of developing kidney disease, researchers find
Catching Covid significantly raises the risk of developing deadly kidney disease, research has shown. The virus was found to increase the chances that patients will develop the incurable condition by around 50 per cent. [...]
New Toothpaste Stops Gum Disease Without Harming Healthy Bacteria
Researchers have developed a targeted approach to combat periodontitis without disrupting the natural balance of the oral microbiome. The innovation could reshape how gum disease is treated while preserving beneficial bacteria. The human mouth [...]
Plastic Without End: Are We Polluting the Planet for Eternity?
The Kunming Montreal Global Biodiversity Framework calls for the elimination of plastic pollution by 2030. If that goal has been clearly set, why have meaningful measures that create real change still not been implemented? [...]
Scientists Rewire Natural Killer Cells To Attack Cancer Faster and Harder
Researchers tested new CAR designs in NK-92 cells and found the modified cells killed tumor cells more effectively, showing stronger anti-cancer activity. Researchers at the Ribeirão Preto Blood Center and the Center for Cell-Based [...]
New “Cellular” Target Could Transform How We Treat Alzheimer’s Disease
A new study from researchers highlights an unexpected player in Alzheimer’s disease: aging astrocytes. Senescent astrocytes have been identified as a major contributor to Alzheimer’s progression. The cells lose protective functions and fuel inflammation, particularly in [...]
Treating a Common Dental Infection… Effects That Extend Far Beyond the Mouth
Successful root canal treatment may help lower inflammation associated with heart disease and improve blood sugar and cholesterol levels. Treating an infected tooth with a successful root canal procedure may do more than relieve [...]
Microplastics found in prostate tumors in small study
In a new study, researchers found microplastics deep inside prostate cancer tumors, raising more questions about the role the ubiquitous pollutants play in public health. The findings — which come from a small study of 10 [...]
All blue-eyed people have this one thing in common
All Blue-Eyed People Have This One Thing In Common Blue Eyes Aren’t Random—Research Traces Them Back to One Prehistoric Human It sounds like a myth at first — something you’d hear in a folklore [...]
Scientists reveal how exercise protects the brain from Alzheimer’s
Researchers at UC San Francisco have identified a biological process that may explain why exercise sharpens thinking and memory. Their findings suggest that physical activity strengthens the brain's built in defense system, helping protect [...]
NanoMedical Brain/Cloud Interface – Explorations and Implications. A new book from Frank Boehm
New book from Frank Boehm, NanoappsMedical Inc Founder: This book explores the future hypothetical possibility that the cerebral cortex of the human brain might be seamlessly, safely, and securely connected with the Cloud via [...]
Deadly Pancreatic Cancer Found To “Wire Itself” Into the Body’s Nerves
A newly discovered link between pancreatic cancer and neural signaling reveals a promising drug target that slows tumor growth by blocking glutamate uptake. Pancreatic cancer is among the most deadly cancers, and scientists are [...]
This Simple Brain Exercise May Protect Against Dementia for 20 Years
A long-running study following thousands of older adults suggests that a relatively brief period of targeted brain training may have effects that last decades. Starting in the late 1990s, close to 3,000 older adults [...]
Scientists Crack a 50-Year Tissue Mystery With Major Cancer Implications
Researchers have resolved a 50-year-old scientific mystery by identifying the molecular mechanism that allows tissues to regenerate after severe damage. The discovery could help guide future treatments aimed at reducing the risk of cancer [...]
This New Blood Test Can Detect Cancer Before Tumors Appear
A new CRISPR-powered light sensor can detect the faintest whispers of cancer in a single drop of blood. Scientists have created an advanced light-based sensor capable of identifying extremely small amounts of cancer biomarkers [...]
Blindness Breakthrough? This Snail Regrows Eyes in 30 Days
A snail that regrows its eyes may hold the genetic clues to restoring human sight. Human eyes are intricate organs that cannot regrow once damaged. Surprisingly, they share key structural features with the eyes [...]
